Business Wire

KYMCO

16.11.2023 11:27:28 CET | Business Wire | Press release

Share
KYMCO Ignites Electric Revolution at EICMA 2023 with the Game-changing Ionex EV Solution

Building on the pinnacle of over 25 years of EV innovation, KYMCO announced three ground-breaking technologies to accelerate the mass-adoption of electric motorcycles: The Ionex Battery-as-a-Service Solution for Energy Companies, the Ionex Battery Metering Unit for EV Manufacturers, and the Ionex Energy Station for Battery-swapping Network Operators. "Today, we stand on the brink of a remarkable transformation in the world of mobility. A shift that reshapes the way we move, a change that KYMCO leads," said Allen Ko, Chairman of KYMCO.

KYMCO's Vision: A World with Electric Motorcycles Everywhere

KYMCO sees Energy Companies provide riders with battery services for electric motorcycles. With this battery service, the riders receive batteries from energy companies with guaranteed performance and pay only for actual battery usage. Riders no longer need to buy batteries when purchasing their vehicle.

KYMCO sees EV Manufacturers introduce electric motorcycles with integrated onboard battery metering. Every electric motorcycle works with the Energy Companies' battery service. Without the costs of the batteries, electric motorcycles are more affordable than ever before.

KYMCO sees Battery-swapping Network Operators deploying thousands of battery-swapping stations, forever erasing range anxiety. Battery-swapping networks provide riders with zero-wait charging and unlimited range.

More profoundly, KYMCO sees riders choosing from a wide variety of electric motorcycles made by various manufacturers and battery service plans that best match their lifestyles. For energy replenishment, riders charge their vehicle in the garage or charge their battery in the house. In the city, riders swap on the go at the nearest battery-swapping station. And while traveling, riders get unlimited range from the extensive battery-swapping network to power all their journeys.

Ionex EV Solution: The True Arrival of the Electric Era

To address all current challenges and future ambitions to fulfill KYMCO's vision, Chairman Ko announced three ground-breaking technologies to propel all stakeholders to collaborate as the Ionex Open Consortium, an EV ecosystem that brings affordable, convenient, and sustainable electric mobility to all, the true arrival of the electric era.

The Ionex Battery-as-a-Service Solution for Energy Companies, the Ionex Battery Metering Unit for EV Manufacturers, and the Ionex Energy Station for Battery-swapping Network Operators make up the revolutionary Ionex EV Solution. The Ionex EV Solution aims to benefit every stakeholder in electric mobility, especially all consumers, businesses, and governments wishing to go electric.

"We look forward to seeing the impact the Ionex EV Solution will have on Southeast Asia's fast-developing EV ecosystem. We see its potential to bring about more affordable and convenient electric mobility," expressed Chuck Kim, Managing Director of Group Business Development and Capital Markets, Grab.

"Right here, right now, marks the inflection point of the electric era," said Allen Ko. "KYMCO's game-changing Ionex EV Solution is paving the way for all stakeholders to jointly transition to the electric future. I invite everyone to join us on this transformative journey."

About KYMCO

KYMCO is a brand with a rich history spanning nearly 60 years in the powersport industry. They focus on innovation, quality, style and have established themselves as a leading manufacturer of scooters, motorcycles, and ATVs worldwide. Their state-of-the-art manufacturing facilities and use of the latest technologies ensure that every vehicle they produce is reliable and stylish.

KYMCO is committed to reducing the environmental footprint, promoting sustainability, supporting social causes, and giving back to the communities. Whether riders seek a sleek and sporty scooter or a rugged and durable ATV, KYMCO has something for everyone. KYMCO is a brand that embodies the best of what the powersport industry offers - innovation, quality, style, and a commitment to making the world a better place.

You can learn more about KYMCO at www.kymco.com

Learn more about Ionex at www.ionexenergy.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231115883583/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release

The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u

Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release

Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata

LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release

LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The

“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release

Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the

Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release

Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye